Comparison of health-related quality of life among patients using novel oral anticoagulants or warfarin for non-valvular atrial fibrillation

被引:22
|
作者
Balci, Kevser Gulcihan [1 ]
Balci, Mustafa Mucahit [1 ]
Canpolat, Ugur [1 ]
Sen, Fatih [1 ]
Akboga, Mehmet K. [1 ]
Suleymanoglu, Muhammed [1 ]
Kuyumcu, Serdar [1 ]
Maden, Orhan [1 ]
Selcuk, Hatice [1 ]
Selcuk, Mehmet Timur [1 ]
机构
[1] Turkiye Yuksek Ihtisas Res & Educ Hosp, Dept Cardiol, Ankara, Turkey
来源
ANATOLIAN JOURNAL OF CARDIOLOGY | 2016年 / 16卷 / 07期
关键词
atrial fibrillation; warfarin; apixaban; dabigatran; quality of life; anxiety; HOSPITAL ANXIETY; DEPRESSION; GUIDELINES; MANAGEMENT; VALIDITY; THERAPY; DISEASE; IMPACT;
D O I
10.5152/AnatolJCardiol.2015.6334
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The aim of this study was to compare health-related quality of life (HRQoL) measures between novel oral anticoagulants (NOACs) and warfarin-treated Turkish patients who had been started on oral anticoagulants (OACs) due to non-valvular atrial fibrillation (AF) and to determine the effects of OACs on patient's emotional status, anxiety and depression. Methods: A total of 182 patients older than 18 years with non-valvular AF and being treated with OACs for at least 6 months according to current AF guidelines who were admitted to outpatient clinics between July 2014 and January 2015 were included in this cross-sectional study. The exclusion criteria were receiving OACs for conditions other than non-valvular AF and being unable to answer the questionnaire. A questionnaire was administered to all participants to evaluate HRQoL, depression and anxiety. The mean differences between the groups were compared using Student's t-test; the Mann-Whitney U test was applied for comparisons of the medians. Results: The annual number of hospital admissions was significantly higher in the warfarin group (p<0.001), and all HRQoL scores were significantly lower and Hospital Anxiety and Depression Scale (HADS) score was higher in the warfarin group (p<0.001). History of any type of bleeding was significantly higher in the warfarin group (p<0.001). However, none of the patients had major bleeding. Among patients who experienced bleeding, all HRQoL scores were significantly lower and HADS score was significantly higher (p<0.001 and p=0.002, respectively). Conclusion: Warfarin-treated patients had higher levels of self-reported symptoms of depression and anxiety and compromised HRQoL when compared with NOAC-treated patients. The results may be explained by higher rates of bleeding episodes and higher number of hospital admissions, which may cause restrictions in life while on warfarin treatment.
引用
收藏
页码:474 / 481
页数:8
相关论文
共 50 条
  • [41] Willingness to Pay for Novel Oral Anticoagulants in Non-Valvular Atrial Fibrillation and Deep Vein Thrombosis Patients
    Lau, K. T.
    Poh, T. E.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 249 : S42 - S43
  • [42] Cost-effectiveness of non-Vitamin-K oral anticoagulants compared to warfarin in patients with non-valvular atrial fibrillation
    Harenberg, J.
    Krejczy, M.
    Wehling, M.
    Obermann, K.
    Lip, G. Y. H.
    EUROPEAN HEART JOURNAL, 2014, 35 : 1107 - 1107
  • [43] COST-EFFECTIVENESS ANALYSIS OF NEW ORAL ANTICOAGULANTS COMPARED TO WARFARIN IN THAI PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
    Dilokthornsakul, P.
    Nathisuwan, S.
    Krittayaphong, R.
    Chutinet, A.
    Permsuwan, U.
    VALUE IN HEALTH, 2018, 21 : S30 - S31
  • [44] Association between oral anticoagulants and risk of dementia in patients with non-valvular atrial fibrillation
    Rahman, Alvi
    Michaud, Jonathan
    Dell'Aniello, Sophie
    Moodie, Erica
    Brophy, James M.
    Durand, Madeleine
    Guertin, Jason
    Boivin, Jean-Francois
    Renoux, Christel
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 631 - 631
  • [45] Atrial fibrillation, oral anticoagulants and health related quality of life
    Apsite, Ketija
    Lurina, Baiba
    Tupahins, Andris
    Voicehovskis, Vladimirs
    Ivascenko, Tarass
    Kalejs, Oskars
    Lejnieks, Aivars
    COR ET VASA, 2018, 60 (06) : E597 - E602
  • [46] Oral anticoagulants and concurrent rifampin administration in tuberculosis patients with non-valvular atrial fibrillation
    Hwang, Ki Won
    Choi, Jin Hee
    Lee, Soo Yong
    Lee, Sang Hyun
    Chon, Min Ku
    Lee, Jungkuk
    Kim, Hasung
    Kim, Yong-Giun
    Choi, Hyung Oh
    Kim, Jeong Su
    Park, Yong-Hyun
    Kim, June Hong
    Chun, Kook Jin
    Nam, Gi-Byoung
    Choi, Kee-Joon
    BMC CARDIOVASCULAR DISORDERS, 2023, 23 (01)
  • [47] Effect of new oral anticoagulants on platelet indices in non-valvular atrial fibrillation patients
    Duzen, Irfan Veysel
    Oguz, Elif
    Cekici, Yusuf
    Yavuz, Fethi
    Vuruskan, Ertan
    Sincer, Isa
    Poyraz, Fatih
    Alici, Hayri
    Yuksek, Umit
    Demirtas, Abdullah Orhan
    Sucu, Murat
    HERZ, 2021, 46 (01) : 76 - 81
  • [48] Inappropriate dose of direct oral anticoagulants therapy in patients with non-valvular atrial fibrillation
    Ito, M.
    Kaikita, K.
    Sueta, D.
    Ishii, M.
    Oimatsu, Y.
    Mitsuse, T.
    Arima, Y.
    Iwashita, S.
    Takahashi, A.
    Kanazawa, H.
    Kaneko, S.
    Kanemaru, Y.
    Kiyama, T.
    Yamabe, H.
    Tsujita, K.
    EUROPEAN HEART JOURNAL, 2018, 39 : 485 - 486
  • [49] Renal outcomes in Asian patients receiving oral anticoagulants for non-valvular atrial fibrillation
    Shahzada, Tayyab Salim
    Guo, Cosmos L.
    Lee, Alex P. W.
    HONG KONG MEDICAL JOURNAL, 2022, 28 (01) : 24 - 32
  • [50] Dosing of Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation and Renal Dysfunction
    Rymer, Jennifer A.
    Webb, Laura E.
    Wang, Tracy Y.
    CIRCULATION, 2021, 144